RVNC News and Press, Revance Therapeutics Inc. From 03/28/22

- Two presentations highlighting data on DaxibotulinumtoxinA for Injection, including Revance’s first oral presentation of the ASPEN-1 Phase 3 clinical trial data, and one poster detailing the positive topline results from the ASPEN Open Label Study (OLS), which demonstrated lo...

Do You Have These Biotech Stocks On Your March 2022 Watchlist? Biotech stocks are often seen as a segment of the market that has the potential to thrive regardless of the broader stock market sentiment. Essentially, biotech companies are high-risk, high-reward investments. This ...

- $300 million note purchase agreement includes committed borrowings of $200 million and an additional option of uncommitted borrowings of up to $100 million - Cash runway extended into 2024 with $100 million in notes issued at closing and an additional committed $100 million ...

Revance Therapeutics (NASDAQ:RVNC) has resubmitted the Biologics License Application for DaxibotulinumtoxinA for moderate to severe glabellar lines. The resubmission follows a Complete Response Letter received in October. The letter noted deficiencies found during an FDA inspection at th...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection f...

Revance Therapeutics, Inc. (RVNC) Q4 2021 Earnings Conference Call February 28, 2022, 04:30 PM ET Company Participants Jessica Serra – Head, IR & and ESG Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO Conference Call Participants Ken Cacciatore - Cowen and Company Ale...

Revance Therapeutics press release (NASDAQ:RVNC): Q4 GAAP EPS of -$0.93 beats by $0.09. Revenue of $25.95M (+133.8% Y/Y) beats by $1.22M. For further details see: Revance Therapeutics GAAP EPS of -$0.93 beats by $0.09, revenue of $25.95M beats by $1.22M

- Announces the completion of three consecutive drug substance lots and one drug product lot as part of the qualification of new working cell bank, supporting BLA resubmission - Fourth quarter and full year 2021 revenue for the RHA® Collection of dermal fillers of $23.8 m...

ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...

Conference Call Scheduled for Monday, February 28, 2022 at 4:30 p.m. ET. Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release fourth quarte...